Wells Fargo initiated coverage of Definium Therapeutics (DFTX) on July 27, 2026. Analyst Benjamin Burnett assigned the biotechnology firm an Overweight rating.
The firm set a price target of $68.00 per share. This target suggests significant upside from the recent trading price of $43.17.
The positive outlook centers on the development of DT120 for mood disorders. Definium is currently conducting Phase 3 programs for major depressive disorder and generalized anxiety disorder.
This rating reflects a growing positive consensus among analysts. Several other firms have recently upgraded their outlook on the company’s prospects.